Dynavax Technologies Corp. signed a deal with GlaxoSmithKline plc to develop endosomal toll-like receptor (TLR) inhibitors targeting immunoinflammatory diseases, which could potentially be worth more than $810 million for the Berkeley, Calif.-based biotech. Read More
Work in the Dec. 14, 2008 issue of Nature Medicine solves an old riddle: Why a 1960's vaccine for respiratory syncytial virus, far from being protective, instead exacerbated disease - a misadventure which, senior author Fernando Polack told BioWorld Today, "has been a major factor hampering vaccine development against RSV" to this day. (BioWorld Today) Read More
